Labcorp Holdings Inc. (LH) shareholders
Close on Nov 17, 2026Market cap $29.90BP/E 30.2Yield 0.78%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,331,017 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 6,201,512 | 7.52% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,574,261 | 8.10% | $1.84B | +129,405 | 0.03% |
| Vanguard Capital Management LLC | 5,362,254 | 6.60% | $1.50B | −13,866 | 0.03% |
| Victory Capital Management Inc | 4,837,573 | 5.96% | $1.35B | +210,447 | 0.76% |
| State Street Corp | 3,907,656 | 4.81% | $1.09B | +44,485 | 0.03% |
| Vanguard Portfolio Management LLC | 3,678,798 | 4.53% | $1.03B | −1,863 | 0.05% |
| Boston Partners | 3,051,690 | 3.76% | $854.20M | +682,894 | 0.76% |
| Allspring Global Investments Holdings, LLC | 2,236,957 | 2.75% | $635.03M | +10,511 | 0.97% |
| Geode Capital Management, LLC | 2,188,890 | 2.70% | $610.44M | +2,948 | 0.03% |
| Select Equity Group, L.P. | 1,981,948 | 2.44% | $554.95M | −192,837 | 2.74% |
| FMR LLC | 1,904,870 | 2.35% | $533.36M | +616,459 | 0.02% |
| Morgan Stanley | 1,609,447 | 1.98% | $450.65M | +111,420 | 0.02% |
| Dimensional Fund Advisors LP | 1,367,166 | 1.68% | $382.80M | +34,391 | 0.07% |
| JPMorgan Chase & Co | 1,268,384 | 1.56% | $354.62M | −264,339 | 0.02% |
| Invesco Ltd. | 1,237,676 | 1.52% | $346.55M | −78,521 | 0.03% |
| Nordea Investment Management Ab | 915,939 | 1.13% | $254.72M | −129,203 | 0.21% |
| UBS Asset Management Americas Inc | 887,431 | 1.09% | $248.48M | −12,771 | 0.05% |
| Northern Trust Corp | 883,076 | 1.09% | $247.26M | −114,334 | 0.03% |
| Wellington Management Group Llp | 855,596 | 1.05% | $239.57M | −103,543 | 0.04% |
| American Century Companies Inc | 845,023 | 1.04% | $236.61M | +34,218 | 0.10% |
| Bank Of America Corp /De/ | 812,270 | 1.00% | $227.44M | +87,459 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,043 | 79M | 97.9% | 107 / 358 | 390 / 72 | 6M | 4M |
| Q1 2026 | 1,022 | 78M | 96.3% | 107 / 332 | 378 / 90 | 14M | 7M |
| Q4 2025 | 1,016 | 80M | 99.0% | 140 / 307 | 387 / 105 | 10M | 8M |
| Q3 2025 | 996 | 79M | 96.7% | 107 / 314 | 378 / 59 | 5M | 7M |
| Q2 2025 | 962 | 81M | 99.9% | 104 / 339 | 360 / 91 | 9M | 5M |
| Q1 2025 | 963 | 78M | 96.3% | 115 / 330 | 351 / 49 | 6M | 5M |
| Q4 2024 | 912 | 78M | 96.3% | 116 / 337 | 333 / 92 | 7M | 7M |
| Q3 2024 | 906 | 78M | 96.6% | 159 / 299 | 302 / 58 | 14M | 6M |
| Q2 2024 | 811 | 79M | 97.6% | 809 / 0 | 0 / 0 | 79M | 0M |
| Q1 2024 | 3 | 0M | 0.0% | 2 / 0 | 0 / 3 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0.0% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q3 2023 | 3 | 0M | 0.0% | 0 / 3 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
711 funds held LH in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,603,810 | 3.21% | $729.07M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,124,615 | 2.62% | $594.89M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 1,776,838 | 2.19% | $497.51M | 0.22% | Jun 30, 2026 |
| Allspring Special Mid Cap Value Fund | 1,536,100 | 1.89% | $430.11M | 3.19% | Jun 30, 2026 |
| Victory Sycamore Established Value Fund | 1,445,000 | 1.78% | $404.60M | 2.62% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,128,386 | 1.39% | $315.95M | 0.04% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,060,876 | 1.31% | $275.89M | 0.03% | May 31, 2026 |
| Victory Pioneer Fund | 1,051,948 | 1.30% | $294.55M | 2.63% | Jun 30, 2026 |
| Vanguard Value Index Fund | 779,826 | 0.96% | $218.35M | 0.09% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 694,336 | 0.86% | $214.69M | 0.22% | Jul 31, 2026 |
| Fidelity Low-Priced Stock Fund | 684,395 | 0.84% | $211.61M | 0.85% | Jul 31, 2026 |
| Vanguard Windsor Ii Fund | 622,300 | 0.77% | $192.42M | 0.29% | Jul 31, 2026 |
| The Hartford Dividend And Growth Fund | 610,718 | 0.75% | $188.83M | 1.00% | Jul 31, 2026 |
| Disciplined Value Mid Cap Fund | 598,151 | 0.74% | $167.48M | 0.72% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 579,364 | 0.71% | $162.22M | 0.40% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adam H. Schechter | President & CEO, Director | 102,565 | 0.13% | Aug 12, 2026 |
| Brian J. Caveney | EVP, Pres of BLS, CMO & CSO | 34,562 | 0.04% | Nov 12, 2026 |
| Bryan T. Vaughn | EVP and President, Diagnostics | 6,845 | 0.01% | Nov 5, 2026 |
| Akinbolade Oyegunwa | EVP, CIO & CTO | 5,316 | 0.01% | Nov 3, 2026 |
| Jonathan C. Meltzer | EVP, COO | 3,620 | 0.00% | Sep 3, 2026 |
| Amy B. Summy | EVP, Chief Marketing Officer | 6,956 | 0.01% | Aug 6, 2026 |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 1,770 | 0.00% | Aug 5, 2026 |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 3,904 | 0.00% | Jul 6, 2026 |
| Megan D. Bailey | EVP, Pres, Central Labs & Intl | 5,332 | 0.01% | Mar 30, 2026 |
| Anita Z. Graham | EVP, CHRO | 5,185 | 0.01% | Mar 30, 2026 |
| Mark S. Schroeder | EVP, Pres Diagnostics & COO | 15,777 | 0.02% | Mar 30, 2026 |
| der Vaart Sandra D. van | EVP, Corporate Affairs | 6,239 | 0.01% | Mar 30, 2026 |
| Julia Aijun Wang | Chief Financial Officer, EVP | 1,817 | 0.00% | Feb 13, 2026 |
| Glenn A. Eisenberg | Executive Vice President | 41,550 | 0.05% | Mar 31, 2025 |
| Lance Berberian | EVP, Special Advisor, Strategy | 20,005 | 0.02% | Mar 31, 2025 |
| Richelle P. Parham | Director | 2,288 | 0.00% | Nov 3, 2026 |
| Kerrii B. Anderson | Director | 6,851 | 0.01% | Aug 18, 2026 |
| Kirsten Marie Kliphouse | Director | 3,160 | 0.00% | Feb 13, 2026 |
| Peter M. Neupert | Director | 13,784 | 0.02% | Feb 13, 2026 |
| Jeffrey A. Davis | Director | 5,460 | 0.01% | Feb 13, 2026 |
| Garheng Kong | Director | 13,739 | 0.02% | Feb 13, 2026 |
| Paul Rothman | Director | 2,571 | 0.00% | Feb 13, 2026 |
| Kathryn E. Wengel | Director | 4,133 | 0.01% | Feb 13, 2026 |
| John H. Sampson | Director | – | – | Feb 12, 2026 |
| Carulla Victor Bulto | Director | – | – | Feb 12, 2026 |
| Dwight Gary Gilliland | Director | 6,656 | 0.01% | Aug 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian J. Caveney EVP, Pres of BLS, CMO & CSO | Nov 10, 2026 | Sale | −2,000 | $372.04 | $744.08K | 34,562 |
| Bryan T. Vaughn EVP and President, Diagnostics | Nov 3, 2026 | Sale(10b5-1 plan) | −306 | $353.70 | $108.23K | 6,845 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Nov 2, 2026 | Tax withholding | −118 | $355.59 | $41.96K | 5,316 |
| Bryan T. Vaughn EVP and President, Diagnostics | Nov 2, 2026 | Tax withholding | −194 | $355.59 | $68.98K | 7,151 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Nov 1, 2026 | Option exercise | +370 | – | – | 5,434 |
| Bryan T. Vaughn EVP and President, Diagnostics | Nov 1, 2026 | Option exercise | +500 | – | – | 7,345 |
| Richelle P. Parham Director | Oct 30, 2026 | Sale | −1,078 | $361.22 | $389.40K | 2,288 |
| Kerrii B. Anderson Director | Aug 17, 2026 | Sale(10b5-1 plan) | −3,000 | $318.02 | $954.06K | 6,563 |
| Adam H. Schechter President & CEO, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −4,669 | $320.37 | $1.50M | 102,565 |
| Amy B. Summy EVP, Chief Marketing Officer | Aug 4, 2026 | Sale | −924 | $306.74 | $283.43K | 6,956 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Sale | −82 | $309.22 | $25.36K | 1,770 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Option exercise | +1,338 | $209.25 | $279.98K | 3,108 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Sale | −1,338 | $309.23 | $413.75K | 1,770 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −92 | $286.19 | $26.33K | 3,904 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 2, 2026 | Sale(10b5-1 plan) | −234 | $286.19 | $66.97K | 6,746 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 1, 2026 | Tax withholding | −73 | $283.88 | $20.72K | 3,996 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 1, 2026 | Option exercise | +256 | – | – | 4,069 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 1, 2026 | Option exercise | +327 | – | – | 7,073 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 1, 2026 | Tax withholding | −93 | $283.88 | $26.40K | 6,980 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jun 8, 2026 | Sale(10b5-1 plan) | −762 | $263.89 | $201.08K | 3,813 |
| Adam H. Schechter President & CEO, Director | May 11, 2026 | Sale(10b5-1 plan) | −5,903 | $254.50 | $1.50M | 107,234 |
| Jonathan C. Meltzer EVP, Operations | Mar 27, 2026 | Sale(10b5-1 plan) | −839 | $267.05 | $224.05K | 3,620 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 27, 2026 | Sale(10b5-1 plan) | −1,633 | $267.05 | $436.09K | 1,852 |
| Adam H. Schechter President & CEO, Director | Mar 26, 2026 | Award | +58,470 | – | – | 139,243 |
| Adam H. Schechter President & CEO, Director | Mar 26, 2026 | Tax withholding | −26,106 | $268.38 | $7.01M | 113,137 |
| Jonathan C. Meltzer EVP, Operations | Mar 26, 2026 | Tax withholding | −711 | $268.38 | $190.82K | 4,459 |
| Jonathan C. Meltzer EVP, Operations | Mar 26, 2026 | Award | +2,388 | – | – | 5,170 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 26, 2026 | Award | +2,388 | – | – | 4,240 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 26, 2026 | Tax withholding | −755 | $268.38 | $202.63K | 3,485 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Mar 26, 2026 | Tax withholding | −382 | $268.38 | $102.52K | 5,064 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Mar 26, 2026 | Award | +1,340 | – | – | 5,446 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Mar 26, 2026 | Tax withholding | −451 | $268.38 | $121.04K | 4,575 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Mar 26, 2026 | Award | +1,584 | – | – | 5,026 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Tax withholding | −863 | $268.38 | $231.61K | 36,492 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Award | +1,986 | – | – | 37,355 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Tax withholding | −4,042 | $268.38 | $1.08M | 35,369 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Award | +9,304 | – | – | 39,411 |
| Anita Z. Graham EVP, CHRO | Mar 26, 2026 | Tax withholding | −2,879 | $268.38 | $772.67K | 5,185 |
| Anita Z. Graham EVP, CHRO | Mar 26, 2026 | Award | +6,604 | – | – | 8,064 |
| Megan D. Bailey EVP, Pres, Central Labs & Intl | Mar 26, 2026 | Award | +1,184 | – | – | 5,332 |
| Megan D. Bailey EVP, Pres, Central Labs & Intl | Mar 26, 2026 | Tax withholding | −481 | $268.38 | $129.09K | 4,851 |
| Amy B. Summy EVP, Chief Marketing Officer | Mar 26, 2026 | Tax withholding | −1,836 | $268.38 | $492.75K | 7,880 |
| Amy B. Summy EVP, Chief Marketing Officer | Mar 26, 2026 | Award | +3,994 | – | – | 9,716 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Award | +9,304 | – | – | 15,777 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Tax withholding | −4,600 | $268.38 | $1.23M | 11,177 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Award | +2,968 | – | – | 14,145 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Tax withholding | −1,468 | $268.38 | $393.98K | 12,677 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Mar 26, 2026 | Tax withholding | −2,722 | $268.38 | $730.53K | 6,239 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Mar 26, 2026 | Award | +6,382 | – | – | 8,961 |
| Bryan T. Vaughn EVP, Diagnostics | Mar 26, 2026 | Tax withholding | −451 | $268.38 | $121.04K | 6,746 |
| Bryan T. Vaughn EVP, Diagnostics | Mar 26, 2026 | Award | +1,584 | – | – | 7,197 |
| Adam H. Schechter President & CEO, Director | Mar 3, 2026 | Sale | −8,705 | $279.96 | $2.44M | 80,773 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Feb 27, 2026 | Sale | −547.54 | $284.91 | $156.00K | 2,579 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 24, 2026 | Sale | −1,500 | $286.31 | $429.47K | 30,107 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −666 | $277.94 | $185.11K | 1,852 |
| Jonathan C. Meltzer EVP, Operations | Feb 12, 2026 | Sale(10b5-1 plan) | −87 | $290.42 | $25.27K | 2,782 |
| Garheng Kong Director | Feb 11, 2026 | Option exercise | +897 | – | – | 13,739 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 11, 2026 | Tax withholding | −211 | $289.89 | $61.17K | 31,607 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 11, 2026 | Option exercise | +740 | – | – | 31,818 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Feb 11, 2026 | Option exercise | +376 | – | – | 3,225 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Labcorp's stock actually held short. Settlement fails (shares not delivered on time) peaked at 254 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Brian J. Caveney Officer | Nov 10, 2026 | 2,000 | $744.08K | Nov 10, 2026 | Restricted Stock Vesting |
| Megan D. Bailey Former Officer | Nov 4, 2026 | 3,035 | $1.10M | Nov 4, 2026 | Stock Option Exercise |
| Bryan T. Vaughn Officer | Nov 3, 2026 | 306 | $108.23K | Nov 3, 2026 | Restricted Stock Vesting |
| Richelle P. Parham Director | Oct 30, 2026 | 1,078 | $389.40K | Oct 30, 2026 | Restricted Stock Vesting |
| Kerrii B. Anderson Director | Aug 17, 2026 | 3,000 | $954.39K | Aug 17, 2026 | Restricted Stock Awards |
| Adam H. Schechter Officer, Director | Aug 11, 2026 | 4,669 | $1.50M | Aug 11, 2026 | Restricted Stock Vesting |
| Amy B. Summy Officer | Aug 4, 2026 | 924 | $283.43K | Aug 4, 2026 | Restricted Stock Vesting |
| Kathryn W. Kyle Officer | Jul 2, 2026 | 92 | $26.33K | Jul 2, 2026 | Restricted Stock Vesting |
| Bryan T. Vaughn Officer | Jul 2, 2026 | 234 | $66.97K | Jul 2, 2026 | Restricted Stock Vesting |
| der Vaart Sandra D. van Former Officer | Jul 1, 2026 | 7,138 | $2.00M | Jul 1, 2026 | Stock Option Exercise |
| Kathryn W. Kyle Officer | Jun 8, 2026 | 762 | $201.08K | Jun 8, 2026 | Restricted Stock Vesting |
| Adam H. Schechter Officer, Director | May 11, 2026 | 5,903 | $1.50M | May 11, 2026 | Restricted Stock Vesting |
| der Vaart Sandra D. van Former Officer | May 6, 2026 | 6,238 | $1.60M | May 6, 2026 | Restricted Stock Vesting |
| Jonathan C. Meltzer Officer | Mar 27, 2026 | 839 | $224.05K | Mar 27, 2026 | Restricted Stock Vesting |
| Adam H. Schechter Officer, Director | Mar 3, 2026 | 8,705 | $2.44M | Mar 3, 2026 | Restricted Stock Vesting |
Congress trades
32 trades in Labcorp reported by 10 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| April McClain Delaney MD06 · child | Sold | Aug 25, 2026 | $100K–250K | Sep 9, 2026 |
| April McClain Delaney MD06 · child | Sold (part) | Aug 7, 2026 | $1K–15K | Sep 9, 2026 |
| April McClain Delaney MD06 · child | Sold (part) | Aug 6, 2026 | $1K–15K | Sep 9, 2026 |
| April McClain Delaney MD06 · child | Sold (part) | Aug 5, 2026 | $1K–15K | Sep 9, 2026 |
| Tony Wied WI08 · joint account | Bought | Feb 19, 2026 | $50K–100K | Mar 9, 2026 |
| April McClain Delaney MD06 · child | Bought | Feb 11, 2026 | $1K–15K | Mar 10, 2026 |
| April McClain Delaney MD06 · child | Bought | Feb 4, 2026 | $1K–15K | Mar 10, 2026 |
| April McClain Delaney MD06 · child | Bought | Jan 28, 2026 | $1K–15K | Feb 2, 2026 |
| April McClain Delaney MD06 · child | Bought | Nov 17, 2025 | $1K–15K | Dec 8, 2025 |
| April McClain Delaney MD06 · child | Bought | Oct 31, 2025 | $1K–15K | Nov 4, 2025 |
| April McClain Delaney MD06 · child | Bought | Oct 29, 2025 | $1K–15K | Nov 4, 2025 |
| Rob Bresnahan PA08 | Bought | May 15, 2025 | $1K–15K | May 31, 2025 |
| Rob Bresnahan PA08 | Sold | Apr 8, 2025 | $1K–15K | May 8, 2025 |
| Gilbert Cisneros CA31 | Sold (part) | Mar 31, 2025 | $1K–15K | Apr 7, 2025 |
| April McClain Delaney MD06 · child | Bought | Feb 28, 2025 | $1K–15K | Mar 20, 2025 |
| April McClain Delaney MD06 · child | Bought | Feb 27, 2025 | $1K–15K | Mar 20, 2025 |
| Rob Bresnahan PA08 | Bought | Feb 25, 2025 | $1K–15K | Mar 27, 2025 |
| April McClain Delaney MD06 · child | Bought | Feb 17, 2025 | $1K–15K | Mar 20, 2025 |
| April McClain Delaney MD06 · child | Bought | Feb 8, 2025 | $1K–15K | Mar 20, 2025 |
| April McClain Delaney MD06 · child | Bought | Feb 5, 2025 | $1K–15K | Mar 20, 2025 |
| Rohit Khanna CA17 · child | Bought | Aug 27, 2024 | $1K–15K | Sep 6, 2024 |
| Rohit Khanna CA17 · child | Bought | Jun 14, 2024 | $1K–15K | Jul 8, 2024 |
| John James MI10 | Sold | Mar 6, 2024 | $1K–15K | Sep 2, 2024 180 days late |
| John James MI10 | Bought | Nov 10, 2023 | $1K–15K | Sep 2, 2024 297 days late |
| Bradley S. Schneider IL10 · spouse | Bought | Jan 12, 2018 | $250K–500K | Feb 15, 2018 |
| Bradley S. Schneider IL10 · spouse | Sold | Nov 21, 2017 | $100K–250K | Nov 23, 2017 |
| Bradley S. Schneider IL10 · spouse | Bought | Mar 10, 2017 | $100K–250K | Mar 25, 2017 |
| Ed Whitfield KY01 | Bought | Aug 4, 2015 | $1K–15K | Sep 15, 2015 |
| Thomas MacArthur NJ03 · joint account | Sold | May 27, 2015 | $1K–15K | Jun 7, 2015 |
| Thomas MacArthur NJ03 · joint account | Bought | May 14, 2015 | $1K–15K | Jun 7, 2015 |
| K. Michael Conaway TX11 | Sold | Nov 3, 2014 | $1K–15K | Aug 1, 2015 271 days late |
| K. Michael Conaway TX11 | Bought | Apr 3, 2014 | $1K–15K | Aug 18, 2014 137 days late |
See a number that looks wrong?